Roxro Pharma, a Menlo Park developer of drugs for acute pain management, has won $21.65 million more in commitments to extend its second round of funding, VentureWire reports (sub required).

The financing came from the company’s existing Series B investors: Prospect Ventures, Sutter Hill Ventures, Thomas Weisel Healthcare Venture Partners, Mediphase Venture Partners, Voyager Funds and Fimei SpA, said Roberto Rosenkranz, chairman and chief executive of Roxro. The company raised an original $21.65 million in Series B financing in September 2005 from the same investors.